poisar

Stocks · News reference

Jefferies Maintains 'Buy' Rating on AstraZeneca

Fiscal.ai

Analyst firm Jefferies has reiterated its 'Buy' rating for AstraZeneca, citing the credibility of the company's 2030 revenue targets.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncDelveinsight

    NSCLC Treatment Landscape Shifts as ESMO 2026 Spotlights MET, KRAS, and TROP2 Advances, Says DelveInsight

    The non-small cell lung cancer market is shifting toward precision, biomarker-guided treatment sequencing. ESMO 2026 presented Phase III data showing savolitinib plus osimertinib improved survival in MET-altered EGFR-mutated NSCLC, divarasib outperformed approved KRAS G12C inhibitors, and TROP2-directed ADCs demonstrated durable gains. The 7MM NSCLC market is projected to double from USD 33 billion in 2025 to USD 67 billion by 2036, driven by expanded screening, biomarker-driven therapies, and label expansions into earlier-stage disease.

  2. Globenewswire IncPrecedence Research

    Pharmaceutical Market to Reach USD 3.20 Trillion by 2035 as Obesity and Oncology Drugs Lead Growth and U.S. Pricing Deals and Tariffs Reshape Manufacturing

    The global pharmaceutical market is valued at USD 1.88 trillion in 2026 and is projected to reach USD 3.20 trillion by 2035 at a CAGR of 6.10%. Growth is concentrated in obesity and oncology therapies, with U.S. pricing deals and Section 232 tariffs reshaping manufacturing. North America holds 42% of the market, while companies with strong positions in GLP-1 medicines and cancer therapies are growing significantly faster than the market.

  3. Zacks Investment ResearchNa

    AstraZeneca Stock Up 12% in a Month: Time to Buy, Sell or Hold?

    AstraZeneca reported Q3 2026 revenues of $16.21 billion (up 7% YoY) and core EPS of $2.79, beating consensus estimates. Strong oncology sales growth (16% to $21.9B) and new drug launches support the company's $80 billion 2030 revenue target. However, generic erosion of mature drugs, recent pipeline failures, and China market uncertainties create headwinds. The company maintains mid-to-high single-digit revenue growth guidance for 2026.

  4. Globenewswire IncDelveinsight

    Systemic Sclerosis Market to Exhibit Growth at a 3% CAGR During the Forecast Period (2026–2036) as Emerging Therapies Expand Treatment Opportunities | DelveInsight

    The systemic sclerosis market is valued at USD 1.9 billion in 2025 and is projected to grow at a 3% CAGR through 2036. Growth is driven by increasing disease awareness, diagnostic advancements, and an expanding pipeline of emerging therapies including anifrolumab, belimumab, efzofitimod, and nemolizumab. The U.S. accounts for 55% of the market, with approximately 232K diagnosed cases across the 7MM in 2025.

  5. The Motley FoolTmf Breakfast News

    Breakfast News: Summit’s FDA Setback Isn’t the End

    Summit Therapeutics' shares plunged over 20% after receiving an FDA Complete Response Letter for its cancer drug ivonescimab, failing to meet overall survival statistical requirements in the HARMONi trial. However, analysts view the setback as limited since it affects only second-line treatment, with the drug's main blockbuster potential in first-line settings. Summit has 17 ongoing late-stage trials, strong financial backing from AstraZeneca, and $630 million in cash reserves to continue development.